domingo, 15 de novembro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 17, 2025

You probably shouldn't wait till 70 to claim Social Security. Here's math to open your eyes (but nobody likes to show)

View original at finance.yahoo.com
You probably shouldn't wait till 70 to claim Social Security. Here's math to open your eyes (but nobody likes to show) Wavebreakmedia/envato Moneywise and Yahoo Finance LLC may earn commission or revenue through links in the content below…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Most people don't have portfolios consisting of assets that earn just 0% to 2%. Rather, their portfolios hold a mix of stocks and bonds — which historically have earned closer to 5% above inflation

    80% confidence
  • Average healthy life expectancy in the U.S. is just 63.9 years

    80% confidence
  • Retirees with modest portfolios, health concerns, or a propensity to underspend may see effective discount rates of 6%-8% or more, which shifts the decision strongly towards early filing

    80% confidence
  • Used 8 solid, repeatable money rules to turn $9,800 into a $150B fortune

    80% confidence
  • At age 67, you qualify for full benefits, but if you delay your claim until age 70, you could enjoy a 24% total boost to monthly benefits

    80% confidence
  • Assuming you'll earn about 5% rather than less than 2% on Social Security income can completely change the math; it makes delaying benefits much less attractive

    80% confidence
  • Only 10% of retirees wait until 70 to claim benefits

    80% confidence
  • The average retirement age in the U.S. is 62

    80% confidence
  • Life expectancy is 78.4 years

    80% confidence
  • Taking Social Security benefits as early as possible (age 62 for those born after 1960) could result in lower monthly payments

    80% confidence
  • Nearly 50% of Americans are making 1 big Social Security mistake

    80% confidence
  • Retirees with substantial resources who are less vulnerable to policy or sequence of returns risks may still benefit from delaying until age 70

    80% confidence
  • If you die early, you could be leaving hundreds of thousands of dollars on that table that otherwise could have been spent or given to loved ones or causes one cares about

    80% confidence
  • Simple spreadsheet calculations assume that future dollars are worth almost the same as today's dollars, based on assumption that retiree invests primarily in ultra-safe assets

    80% confidence
  • At 70, your monthly benefit stops increasing

    80% confidence
  • Age 70 is not the most financially rewarding age to initiate benefits unless an individual has a low discount rate and/or is confident they will live several years past their life expectancy

    80% confidence
  • Calculations do not support the presumption that the vast majority of people who choose to start their Social Security retirement benefits before age 70 are making a mistake

    80% confidence
  • Working with a financial advisor can add about 3% to net returns over time

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,995
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,995 factos verificados com a fonte5,580 documentos-fonte arquivados
Consulte estes dados → isubstrate.com